Reset filter
Keywords
Therapeutics ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

145 Search results.
Relevance Rating New first Old first

Eligibility Asthma NCT02347462

- 10/12/15 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations; ODM derived from: https://clinicaltrials.gov/show/NCT02347462

Eligibility Type 2 Diabetes NCT00612794

- 6/13/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00612794

Eligibility Type 2 Diabetes Mellitus NCT02004886

- 6/13/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005); ODM derived from: https://clinicaltrials.gov/show/NCT02004886

Eligibility Type 2 Diabetes Mellitus NCT00605475

- 6/13/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00605475

Eligibility Non-Small Cell Lung Cancer NCT02013206

- 6/4/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02013206

Eligibility Non-Small Cell Lung Cancer NCT00678964

- 6/4/17 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00678964

Eligibility Non-small Cell Lung Cancer NCT00533429

- 6/4/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00533429

Eligibility Non Small Cell Lung Cancer NCT00614965

- 6/2/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV; ODM derived from: https://clinicaltrials.gov/show/NCT00614965

Dialyseprotokoll MEDD MS University Hospital Muenster (UKM)

- 12/6/16 - 1 form, 7 itemgroups, 52 items, 1 language
Itemgroups: General information, Monitoring, Parameters, Concentrate, Medication, Checklist, Comments
Hospital Routine Documentation Form at the University Hospital Muenster. Original Form name: Dialyseprotokoll MEDD MS

Operations Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 10/4/16 - 1 form, 2 itemgroups, 6 items, 1 language
Itemgroups: Patient identification, Operations form
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

Lung cancer (clinical) DSS Metadata Online Registry (METeOR)

- 9/7/16 - 1 form, 6 itemgroups, 47 items, 1 language
Itemgroups: Cancer treatment, Health service event, Patient, Person (address), Person with cancer, Person
Health sector data set specifications from METeOR, Australia's repository for national metadata standards, developed by the Australian Institute of Health and Welfare (http://meteor.aihw.gov.au/content/index.phtml/itemId/345165) Lung cancer (clinical) DSS: The purpose of the Lung cancer (clinical) data set specification (LCCDSS) is to define data standards for the national collection of lung cancer clinical data so that data collected is consistent and reliable. Collection of this data set specification is not mandated but it is recommended as best practice if clinical cancer data are to be collected. It will facilitate more consistent data collection while enabling individual treatment centres or health service areas to develop data extraction and collection processes and policies that are appropriate for their service settings. The Lung cancer (clinical) data set specification is used in conjunction with the Cancer (clinical) data set specification (CCDSS). Mandatory reporting regulations have enabled population-based cancer registries in Australia to collect standard information on all incident cases of cancer apart from non-melanoma skin cancers, from which incidence, mortality and overall survival have been determined and trends monitored. The CCDSS provides a framework for the collection of more detailed and comprehensive clinical data such as stage of cancer at diagnosis, other prognostic characteristics, cancer treatment and patient outcomes. The Lung cancer (clinical) data set specification will support prospective data collection from the time a person with cancer symptoms is referred or first presents to a hospital or specialist through the entire duration of their illness. The definitions used in this data set specification are designed to capture the provision of cancer care on a day-to-day level. They relate to the cancer care pathway and the need to optimise care by correctly diagnosing, evaluating and managing patients with cancer. In addition, end-points and patterns of care can be monitored to understand both the appropriateness and effectiveness of cancer care. The data elements specified provide a framework for: • promoting the delivery of evidence-based care to patients with cancer • facilitating the ongoing improvement in the quality and safety of cancer management in treatment settings • improving the epidemiological and public health understanding of cancer • informing treatment guidelines and professional education • guiding resource planning and the evaluation of cancer control activities They will facilitate the aggregation of data across different treatment centres. The underlying long-term goal is to provide data support to improve outcomes for patients by increasing the quality and length of life. For example, a comparison of the actual management of patients with best practice guidelines may identify shortfalls in treatment and limitations in access to treatment modalities for some patients. Metadata and Classifications Unit Australian Institute of Health and Welfare GPO Box 570 Canberra ACT 2601

Patient Administration Intermittent Prone Positioning Posttraumatic Lung Injury Study

- 9/25/16 - 1 form, 6 itemgroups, 38 items, 2 languages
Itemgroups: Patient identification, Patient administration, Inclusion criteria, Exclusion criteria, Prognostic factors, Randomization
Intermittent prone positioning in the treatment of severe and moderate posttraumatic lung injury (1999). Background: Severe posttraumatic lung injury is characterized by impairment of gas exchange and pulmonary densities. The influence of intermittent prone positioning on pulmonary gas exchange and parenchymal densities was investigated prospectively in patients with pulmonary injury after multiple trauma with blunt chest trauma. Publication granted by Claudia Ose, ZKS UK Essen. Multizentrische prospektive randomisierte Studie zur Überprüfung der prognostischen und therapeutischen Effektivität der dorsoventralen Wechsellagerung bei Patienten mit posttraumatischem akutem Lungenversagen. Freigegeben durch Frau Claudia Ose, ZKS Essen.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial